ReviewCureus2025
Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of a novel oral potential multiple agonist for obesity treatment: multi-target in silico study.Journal of computer-aided molecular design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising pharmacological intervention in obesity management. This systematic review aimed to evaluate the efficacy and safety of semaglutide in promoting weight loss in adults with obesity. A comprehensive literature search was conducted in the PubMed, Scopus, and Web of Science databases, and nine studies met the inclusion criteria. The studies included randomized controlled trials and case-control studies involving participants aged 18-65 years with BMI > 30 kg/m². Semaglutide administered once a week, particularly at a dosage of 2.4 mg, led to a significant mean weight loss of 14.9% compared to 2.4% in the group receiving a placebo (mean difference: -12.4 percentage points; 95% CI: -13.4 to -11.5; P < 0.001). Research has indicated weight reductions between 3 and 15 kg, with greater doses and longer treatment durations, resulting in more substantial decreases. Additionally, semaglutide considerably improved glycemic control, with 57-74% of participants receiving 1.0 mg achieving HbA1c levels below 7.0% (P < 0.0001). The observed improvements in weight and metabolic parameters were consistent across the diverse racial and demographic groups. The most common adverse effects observed were mild-to-moderate gastrointestinal issues, primarily nausea and vomiting. These symptoms were dose-dependent and typically transient, although they caused some participants to discontinue the treatment. Assessment of potential bias using the Cochrane Risk of Bias Tool revealed that most studies had a low overall risk, with some exhibiting moderate risks in areas of performance, detection, and reporting biases. In conclusion, semaglutide is effective as a pharmacological intervention for obesity management, resulting in significant weight loss and improved glycemic control. However, long-term safety data remain scarce, and gastrointestinal side effects may negatively affect patient compliance. Further research is required to optimize dosing strategies, assess cost-effectiveness, and evaluate long-term safety, thus enhancing the clinical utility and accessibility of the drug.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.